wake_up_call_jpg2Back on September 25, 2005, Judge Farnan of the United States District Court for the District of Delaware stayed the litigation between Hasbasit Belting, Inc. v. Rexnord Industries, Inc. (Civil Action 03-185) relating to U.S. Patent 6,523,680. The stay was entered in favor of inter partes reexamination 95/000,072.

Yesterday, the rejection of issued claims 1-14 was reversed at the BPAI (decision here). The refusal to adopt a rejection of claim 6 and 13 was also affirmed. Thus, the Third Party, Rexnord Industries, may find itself on the wrong side of the estoppel equation of 35 USC 315 (c) very shortly.

More importantly, will the court recognize the significant delay to date, and the appeal reversal as justification enough to lift the stay? Continue Reading Case Stayed 5 years in Favor of Inter Partes Patent Reexamination to Restart?

c13The relevance of original patent application prosecution history in patent reexamination remains an unsettled issue at the USPTO. As we discussed last month, the MPEP mandates the application of Phillips v. AWH Corp., 415 F.3d 1303; (Fed. Cir. 2005) (en banc) with regard to according a plain meaning to claim terms.Yet the broadest reasonable interpretation (BRI) looks exclusively at the specification.

Last week, the BPAI addressed the use of prosecution history in according a plain meaning in Ex parte Team Worldwide Corporation (Appeal 2010-002223). In doing so, the Board reversed a rejection applied in reexamination based upon the plain meaning of “body.” In the Patentee’s brief, it was pointed out that the original patent application examiner advanced a similar understanding of the term “body” as that argued by the Patentee in the later patent reexamination. While the Board ultimately adopted the Patentee interpretation, it refused to consider the prosecution history, explaining: Continue Reading Examiner Comments in Prosecution History Discounted as Unskilled?

 

24529214er6Threat of Injunction Dissolves in Flexiteek Litigation

The initiation of patent reexamination for patents subject to concurrent litigation can provide strategic benefits independent of the ultimate outcome of the reexamination. These litigation inspired applications of patent reexamination can be thought of as falling into one of two categories, namely, pre-trial maneuvers or post-trial, damage control.

Pre-trial Maneuvers are those patent reexaminations initiated to potentially enhance a defendant’s battle in the district court.  For example, patent reexamination may be sought as an avenue to establish objectively reasonable behavior for use in preventing a willfulness finding. (see e.g., the yesterday’s Fairchild Semiconductor press release). Still other defendants initiate patent reexamination concurrent with litigation as a mechanism to leverage more acceptable settlement terms, provide additional fodder for claim construction, or to demonstrate the materiality of a reference subject to an inequitable conduct defense.

Post-trial (damage control) on the other hand, is a litigation inspired use of patent reexamination that seeks to undo the damage inflicted by the ruling of the district court. One of the more well known uses of a patent reexamination filed after a district court judgment was illustrated in In re Translogic Tech., Inc., 504 F.3d 1249, 1257 (Fed. Cir. 2007). Translogic had secured an earlier verdict for significant damages against Hitachi, the appeal reached the CAFC at the same time as the appeal rejecting all claims in reexamination, as a result, the infringement verdict was vacated.

Others have sought to leverage patent reexamination to get out from under, or to prevent an injunction. Recently, Apotex was enjoined from sale of a generic Plavix® until after the patent expires. In attempt to dislodge the injunction, Apotex has sought patent reexamination. The first reexamination was terminated favorably to the Patentee and the second was recently denied; Apotex has been unable to dislodge the injunction to date. Yet, last week, a defendant successfully leveraged a final rejection in patent reexamination to stay the enforcement of a permanent injunction.

Enforcement of Injunction Stayed in View of Patent Reexamination

In Flexiteek v. Plasteak,  (S.D. Fla. 2010) (Cohn, J.), the district court opted to stay the enforcement (order here) of the permanent injunction based upon the status of the related patent reexamination. At trial, Plasteak was found to infringe the subject patent (6,895,881), and held liable for a paltry $79K in damages, but was to be enjoined from further infringement by operation of permanent injunction.

Currently, the original claims of the ‘881 Patent stand finally rejected, however, new claims added during prosecution of the reexamination stand allowed (Advisory Action of 7/1/10).  (As an aside, this reexamination has proceeded faster than almost any I have seen to date, request was filed July 20, 2009, Advisory Action issued June 4, 2010)

In arguing against staying the injunction, Flexiteek pointed out that the patent was not “declared invalid” as stated by the defendants and that years of appeal lay ahead. Flexiteek also noted the existence of the allowed, new claims, and explained that as these new claims contained only minor changes, there would be no intervening rights — thus– Flexiteek argued that the injunction should be entered since the specific rejected claims are largely irrelevant. Not surprisingly, the defendants argued the exact opposite, taking the position that intervening rights would be found based upon the claim changes.

In deciding to stay the enforcement of the injunction, the court labeled the new claim issue as “speculative” and noted the unfairness of enjoining the defendant from infringing a patent “declared invalid,” holding:

The Court finds that the arguments set forth above are speculative. The current circumstances before this Court are that Defendants’ actions are being restrained by a patent which has been declared invalid by the PTO. Accordingly, the Court will not entertain arguments now based on what the parties believe the future may hold. Should the circumstances change in the future, the Plaintiffs make seek relief on the basis of such facts. Defendants are aware of the reexamination proceedings as well as the proposed amendments. The Court concludes that the PTO’s proceedings should govern Defendants’ actions rather than the Court’s Permanent Injunction which is based on a patent which has been declared invalid.

As the damages for past infringement are $79k, the real value to the plaintiff seems to be the keeping the defendant out of the market going forward (injunction). Thus, whether or not the new claims would be entitled to past damages (i.e., no intervening rights) seems largely unimportant for such an inconsequential dollar amount. However, should the court deem that the new claims require further construction the basis for the injunction may be undermined, requiring a new trial, discovery, etc. (the true rationale behind the intervening rights argument in the briefing)

The rejection of the original claims of the ‘881 Patent in patent reexamination seem reasonably based. Assuming the appeal goes forward, the appeal delay will prevent issuance of the new claims. This delay will allow the defendants the freedom to enter the market and practice the invention of the ‘881 patent for the next several years unabated. Thus, going forward with the appeal does not seem like a worthwhile gamble for Flexiteek.

Clearly, the court’s position that the new claims are “speculative” is a bit short sighted. Indeed, the court’s decision to stay the enforcement of the injunction may very well force Flexiteek to simply cancel the rejected claims and return to court with their new claims, in very short order.

reexampendency

(click to enlarge)

One of the threshold questions in considering patent reexamination, whether a patent owner, or third party is:

How long will it take?

This question is also the subject of significant debate when litigants in a concurrent district court proceeding argue for/against staying the proceeding. Defendants will often point to the published PTO statistics which identify a 24-28 month pendency to conclusion (NIRC). Conversely, Patentee’s point out that these published number do not account for appeal processing. As can be seen from the chart above, reexaminations that are contested through to appeal, are taking roughly 5 years (ex parte or inter partes). Thus, it is quite disingenuous for defendants Continue Reading How Long Does Patent Reexamination Really Take?

CAFC to Decide Prosecution Laches in Patent Reissue

Earlier this year we discussed the Ex Parte Tanaka decision of the Board of Patent Appeals & Interferences (BPAI) with respect to “bullet claims”  in patent reissue, now before the CAFC. On June 24, 2010, a second Board decision relating to patent reissue was appealed to the Federal Circuit (Ex Parte Staats).

Although presented in the context of patent reissue, the point of contention in Staats is actually one of prosecution laches and the application of equitable principles to statutory interpretation. In Staats, the Board upheld a rejection of a broadening reissue application as defective under 35 U.S.C. 251 for failing to include the appropriate broadening oath within two years of the original patent issuance. The Board reasoned that although a parent reissue had filed an appropriate broadening oath and identified at least one error, the continuation reissue was not entitled to rely on that oath, despite the continuity between these reissue applications. The BPAI presented the issue as :

This is a case of first impression. Resolution of the case hinges on one fundamental question: Can a continuing reissue application broaden patented claims beyond the statutory two-year period in a manner unrelated to the broadening aspect that was identified within the two-year period? Put another way, is it enough under the law to merely present an intent to broaden that is limited to a particular aspect (e.g., a particular embodiment of the invention) within the two-year period, yet broaden in unforeseeable ways (e.g., pertaining to other embodiments) outside the two-year period?

While the Board noted that the question of interpreting 35 U.S.C. 251 in this manner was a case of first impression, MPEP 1412.03 (IV) was argued by Apple as directly on point (i.e., explicitly authorizing the practice). Curiously, the Board found this aspect of the MPEP ambiguous, and analyzed the statute based upon their understanding of the equitable principles behind the two-year limitation provided by the statute.

In doing so, the BPAI relied heavily on the aspect of foreseeability emphasized in case law addressing prosecution laches. In affirming the rejection, the BPAI surmised:

Since this broadening was completely unforeseeable by the public within the two-year statutory period-a circumstance that is undisputed-it runs counter to the public notice function underpinning § 251 and is therefore improper.

In arriving at their conclusion on equitable principles, the BPAI reviewed the seminal cases in this area (In re Graff, 111 F.3d 874, 877, 42 USPQ2d 1471, 1473-74 (Fed. Cir. 1997) and (In re Doll, 419 F.2d 925, 928, 164 USPQ 218, 220 (CCPA 1970). The Board noted that both of these early decisions supported their conclusion that the manner of broadening must be identified within two years.

Arguably, neither of these cases needed to consider the manner of the broadening. Thus, the Board noted only that the facts of Doll were consistent with their decision, and Graff emphasized the two year requirement. So, to buttress their decision, the Board relied on case law relating to prosecution laches, such as Symbol Techs., Inc. v. Lemelson Med., Educ. & Res. Found., 277 F.3d 1361, 1364 (Fed. Cir. 2002).

However, the cases dealing with foreseeability in the prosecution laches context relate to applications that were prosecuted in secret (i.e., before the days of publication). As reissue applications are published in the Official Gazette, foreseeability with respect to specific changes is only a mouse click away via PAIR. Certainly, in the past, there was significant motivation to purposely delay prosecution in the days of  “submarine applications.”  However, by waiting 8 years to file the continuation reissue application in question, Apple only surrendered enforceable patent term to the public (intervening rights).

There is little motivation for anyone to drag their feet in reissue, likewise, the manner of broadening is not the least bit secret. Interested parties cannot not only track the progress of such broadening publicly, but are provided a mechanism to protest via the submission of prior art under 37 CFR 1.291.

Should be an interesting CAFC opinion, stay tuned.

good-enough3Last Friday, the BPAI issued a decision reversing all rejections in the ex parte reexamination appeal of U.S. Patent 6,513,042. The patent is owned by Test.com and is directed to methods of on-line testing of students (test-takers). The patent was challenged back in April 5, 2006 by the Electronic Frontier Foundation.

The primary issue in this appeal was whether or not antedating declarations (swear behind) required all inventor signatures, or whether or not the declarations can be executed by a representative of the Patent Owner alone. The examiner pointed to aspects of MPEP 715.04 that seemed to imply that all inventors must sign Continue Reading Test.Com Reexamination Concludes with BPAI Reversal

APTOPIX Obama 2008During an interview with ABC news this past Sunday, “This Week” Senior White House Advisor David Axelrod fielded questions on the administration’s plan for economic growth. With the deficit growing, and the Obama White House being assailed for over spending, Mr. Axelrod mentioned several initiatives that will not require further spending, but are expected to benefit the economy.

He described everyone’s favorite multi-year, multi-administration, never ending legislative initiative as follows:

…we’re going to keep launching initiatives, and they don’t all involve spending.

Things like patent reform are things that — is something that we want to pursue so that small businesses and start-up businesses with a good idea can — can — can move without the kind of bureaucratic obstacles that the current patent system provides.

With health care and banking reform seemingly complete, and the Obama administration looking for a cause to rally around that does not involve spending….maybe…oh never mind.

080526155300-largeass=”alignleft” src=”http://www.bioresearchnews.com/wp-content/uploads/2009/09/080526155300-large-300×225.jpg” alt=”080526155300-large” width=”213″ height=”185″ />The USPTO has recently upheld Genetic Technologies Ltd.’s (GTG’s) patent for non-coding DNA technologies.  U.S. Patent No. 5,612,179 titled “Intron sequence analysis method for detection of adjacent locus alleles as haplotypes” claims a method for facilitating the detection of specific gene variations.

The third party initiated ex parte re-examination Control No. 90/010,318, was filed on October, 15, 2008 requesting that each of claims 26-32 be found invalid in view of a new reference, which was not previously cited in the prosecution of the ‘179 patent; namely a printed publication titled “Comparison of Multiple HLA-A Alleles at the DNA Level by Using Southern Blotting and HLAA-A-Specific Probes” by Beverly Koller et al. (“Koller I”).  The request submitted that Koller I raised a substantial new question of patentability and renders claims 26-30 and 32 of the ‘179 patent invalid as anticipated under § 102(b) and claim 31 invalid under § 103(a).  The request further argued that Koller I discloses characterizing the alleles of the multi-allelic HLA-A genetic locus using polymorphisms found in non-coding regions of that locus, including polymorphisms in introns and polymorphisms in flanking regions of the HLA-A locus.

In a reply filed July 24, 2009, GTG argued Continue Reading Genetic Technologies Ltd.’s Non-coding DNA Patent Upheld on Reexamination

Smoke-N-Mirrors_whiteThe Death Rattle of a Troll

As we detailed previously, the NTP patent portfolio has been eviscerated in patent reexamination with over 2200 claims rejected across 8 patents.  All 8 patents are now on appeal to the CAFC, based on my reading of the rejections, it appears unlikely that NTP will be successful in reversing the applied rejections. Much of NTP’s arguments deal with the proper interpretation of claims in patent reexamination, NTP argues that the district court Markman is controlling rather than a broadest reasonable interpretation used by the USPTO. Of course, this argument has been rejected by the CAFC consistently over the years. In re Zletz, 893 F.2d 319, 322, 13 USPQ2d 1320, 1322 (Fed. Cir. 1989); In re Trans Texas Holdings Corp., 498 F.3d 1290, 83 USPQ2d 1835 (Fed. Cir. 2007); and In re Translogic Technology, Inc., 504 F.3d 1249, 84 USPQ2d 1929 (Fed. Cir. 2007). Another substantial component of their arguments is that a certain printed publication (Telenor) was falsified, and does not in fact qualify as prior art; to date this argument has fallen on deaf ears.

As a result of the reexaminations, initiated by both the Director of the USPTO and Research in Motion (RIM), only 36 original claims were confirmed. A single one of these claims, claim 15 of the 960 patent, was held not invalid and infringed by the CAFC in the earlier RIM dispute (method claims 32 and 34 while found infringed at trial were overturned at the CAFC under 35 USC 271 (f)). So, one would expect that with roughly 2% of the earlier claim set still intact, and the entire portfolio set to expire in 2012, that NTP would quietly fade away. Yet, NTP has initiated yet another suit (complaint against Apple here) just last Thursday, perhaps in the hopes of securing further settlements prior to the final CAFC decisions. In doing so, NTP has filed a complaint referencing patents that may be canceled by the CAFC in a matter of months, and has referenced claims added in patent reexamination that do not yet exist as an enforceable property right. Continue Reading NTP’s Last Stand: The Remnants of Patent Reexamination

80px-Baseball_umpire_2004ass=”alignleft size-full wp-image-3003″ title=”80px-Baseball_umpire_2004″ src=”https://www.patentspostgrant.com/wp-content/uploads/2010/07/80px-Baseball_umpire_2004.jpg” alt=”80px-Baseball_umpire_2004″ width=”80″ height=”120″ />In the world of pharmaceuticals, every day counts.  Indeed, when the subject matter is a block-buster drug like Bristol-Myers/Sanofi’s anti-blood clot drug Plavix® every day of U.S. sales averages nearly $15.5 million dollars (reported U.S. sales for 2009 of $5.6 billion).  So, it comes as no surprise that Apotex Inc., a Canadian manufacturer of a generic version of the drug, refuses to sit on the side-lines waiting for the Plavix® patent (U.S. 4,847,265) to expire.  However, the playing field has not been so kind to Apotex. Continue Reading Three Strikes, You’re Out!? Apotex’s Latest Attempt to Invalidate the PLAVIX® Patent Denied by USPTO